Program
Anti-GPC3 T Cell-engaging Antibody AZD9793
Also written as “AZD9793 Intravenous (IV) monotherapy” and “AZD9793 Subcutaneous (SC) monotherapy”.
Its studies are mostly in Carcinoma, Hepatocellular, led by AstraZeneca.
Furthest: phase 2, since Jan 8, 20251 company-led study, 1 open or runningNext primary completion: Jun 30, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 11 open or running | phase 2since Jan 8, 2025 | Jan 8, 2025 | Jun 30, 2027phase 2 · NCT06795022 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 8, 2025First study: phase 2 study in Carcinoma, HepatocellularFirst studyNCT06795022 · 304 planned · United States, China, Hong Kong and more
Ahead
- Jun 30, 2027Primary completion: phase 2 study in Carcinoma, HepatocellularNCT06795022
TargetBeta
“A T-cell engaging (TCE) asymmetric trispecific immunoglobulin G1 (IgG1) antibody targeting the tumor-associated antigen (TAA) glypican-3 (GPC3; GPC-3) and the T-cell surface antigens CD3 and CD8, with potential immunostimulating and antineoplastic activities. Upon administration, anti-GPC3 TCE an…”NCIt, read by Claude
“A T-cell engaging (TCE) asymmetric trispecific immunoglobulin G1 (IgG1) antibody targeting the tumor-associated antigen (TAA) glypican-3 (GPC3; GPC-3) and the T-cell surface antigens CD3 and CD8, ”NCIt, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06795022Carcinoma, Hepatocellular · United States, China, Hong Kong and more | 2 | Recruiting | Jun 30, 2027 | 304 |
How it is read
Names in the registry
- “AZD9793 Intravenous (IV) monotherapy”, 1 entry
- “AZD9793 Subcutaneous (SC) monotherapy”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.